Arbutus Biopharma (ABUS) Short-term Investments (2014 - 2026)

Arbutus Biopharma (ABUS) has reported Short-term Investments for 13 consecutive years, with $71.5 million the latest figure, recorded in Q1 2026.

• Quarterly Short-term Investments fell 5.44% year-over-year to $71.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.5 million (down 5.44% YoY) and the FY2025 annual result came in at $73.5 million, down 14.87% from the prior year.
• Short-term Investments retreated to $71.5 million in Q1 2026 per ABUS's latest filing, from $73.5 million in the prior quarter.
• Over the last five years, Short-term Investments for ABUS reached as high as $125.3 million in Q2 2023 and fell as low as $60.7 million in Q2 2025.
• A 5-year average of $91.9 million and a median of $86.3 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 152.28% — and 2024, when it slumped 36.79%.
• Year by year, Short-term Investments stood at $116.1 million in 2022, then fell by 14.14% to $99.7 million in 2023, then fell by 13.46% to $86.3 million in 2024, then dropped by 14.87% to $73.5 million in 2025, then declined by 2.64% to $71.5 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $71.5 million, $73.5 million, and $71.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.